Dr Martens on Tuesday forecast broadly flat revenue for fiscal 2026, after quarterly sales dipped as the British bootmaker pulled back on discounts as part of its plan to return to profit growth.
Dr Martens has been scaling back discounting and expanding into shoes, sandals and bags as it seeks a return to profit growth in the current financial year. However, tariffs imposed by US President Donald Trump have complicated the bootmaker's targets, adding fresh pressure to costs in its largest market.
Dr Martens, known for its chunky lace-up boots, plans to raise US prices from January, and has shifted production to Vietnam from Laos to blunt the impact of higher US import tariffs.
For the three-month period ended December 28, the company's revenue fell 3.1% to 251 million pounds ($343.42 million), pressured by weaker consumer demand in its European market.
